NCT07109726 - A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Biotech Hunter

Enrollment

205

Participants

Timeline

Start Date

September 23, 2025

Primary Completion Date

December 30, 2028

Study Completion Date

February 28, 2029

Conditions

Breast CancerEndometrial CancerOvarian CancerLung Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaSolid TumorCervical Cancer

Interventions

DRUG

TER-2013

Oral Capsules

DRUG

Fulvestrant injection

Fulvestrant 500 mg Intramuscular Injection

Trial Locations (4)

22031

RECRUITING

NEXT Oncology, Fairfax

28078

RECRUITING

Carolina BioOncology Institute, Huntersville

68130

RECRUITING

Nebraska Cancer Specialists, Omaha

78229

RECRUITING

NEXT Oncology, Austin

All Listed Sponsors

lead

Terremoto Biosciences Inc.

INDUSTRY